Helen Knight

Who Helen Knight is

Helen Knight is Director of Medicines Evaluation at NICE, responsible for designing and operating methods and systems to produce national guidance and other advice on medicines and other relevant therapies for the NHS in England. She holds an academic background in biochemistry and health economics, and has over 20 years of experience in health technology assessment across a wide range of technologies and disease areas. Before joining NICE in the Technology Appraisal Programme in 2007, she spent six years working as a health economist for a health outcomes consultancy. She has provided witness statements to the UK COVID-19 Public Inquiry on behalf of NICE, covering NICE's pandemic response. She is regularly quoted in the UK press on major medicines appraisal decisions, including NICE guidance on semaglutide for weight management and cardiovascular risk reduction.

References for this biography

1. 1.Executive team | NICE — Confirms role title, responsibilities, academic background in biochemistry and health economics, and 20+ years of HTA experience
2. 2.ISPOR 2022 – Helen Knight speaker bio — Confirms she joined NICE's Technology Appraisal Programme in 2007 after 6 years as a health economist in a health outcomes consultancy
3. 3.Witness statement of Helen Knight on behalf of NICE, dated 19/02/2024 – UK COVID-19 Inquiry — Confirms she gave formal evidence to the UK COVID-19 Public Inquiry on behalf of NICE (Module 3)
4. 4.Witness Statement provided by Helen Knight on behalf of NICE, dated 18/11/2024 – UK COVID-19 Inquiry — Confirms second witness statement to UK COVID-19 Public Inquiry (Module 4)
5. 5.Injection for more than a million people to help prevent heart attacks and strokes recommended | NICE — Shows Helen Knight as the named NICE spokesperson quoted on the 2026 semaglutide cardiovascular guidance
6. 6.NICE backs weight loss jab to help prevent heart attacks and strokes | Nursing Times — Press coverage quoting Helen Knight on the 2026 NICE semaglutide recommendation
7. 7.Driving innovation into the hands of health practitioners | Lymphoma Action — Identifies Helen Knight as Director of Medicines Evaluation at NICE and describes her role in HTAs and stakeholder engagement
8. 8.Contact us | NICE — Confirms NICE head office address: 3rd Floor, 3 Piccadilly Place, Manchester M1 3BN; press office email pressoffice@nice.org.uk
9. 9.Helen Knight – NICE Conference 2026 — Confirms role and background; shows her as a named speaker at the NICE Conference 2026

Notable achievements

• Provided witness statements to the UK COVID-19 Public Inquiry (Modules 3 and 4) on behalf of NICE, describing NICE's methods and pandemic response including rapid value assessments of COVID-19 therapeutics such as remdesivir. Source ↗
• Welcomed NICE's 2023 guidance recommending semaglutide (Wegovy) for weight management, which required NHS England to implement recommendations within 3 months of commercial availability. Source ↗
• Quoted as the lead NICE spokesperson on the 2026 recommendation that semaglutide be offered on the NHS to help prevent further heart attacks and strokes in high-risk adults. Source ↗
• Featured as a speaker at the NICE Conference 2026, representing NICE's medicines evaluation directorate. Source ↗

What Helen Knight has said

• “The MHRA's proposed Rare Disease Therapies Regulatory Framework potentially complements NICE's approach that enables NHS patients to receive innovative and promising medicines while additional evidence is gathered on how well they work in practice.”

  Director of Medicines Evaluation at the National Institute for Health and Care Excellence · Rare diseases · 30 Sept 2026 · Landmark new plans bring treatments for rare diseases a step closer ↗

• “This recommendation is a significant milestone for people with COPD. It offers patients an effective, targeted therapy that has shown impressive results - reducing flare-ups by around a third while improving lung function. This is better for patients and better for the NHS.”

  NICE's Director of Medicines Evaluation · Respiratory (asthma/COPD) · 30 Sept 2026 · NICE recommends new breakthrough treatment for COPD ↗

• “This recommendation marks a significant milestone for people with COPD, offering an effective and targeted therapy with strong results. This is better for patients and the NHS.”

  NICE Director of medicines evaluation · Respiratory (asthma/COPD) · 30 Sept 2026 · NICE approves new COPD treatment that cuts flare-ups by 30% ↗

• “The independent appeal panel has ruled that some elements the committee used to inform its decision-making in relation to the cost-effectiveness of donanemab and lecanemab need further consideration.”

  director of medicines evaluation at Nice · Dementia · 30 Sept 2026 · NHS will reconsider approving Alzheimer’s ‘wonder drugs’ ↗

• “Our recommendation of dupilumab was a significant milestone for people with COPD. It offers people an effective, targeted therapy that has shown impressive results - reducing flare-ups and improving lung function.”

  director of medicines evaluation at NICE · Respiratory (asthma/COPD) · 30 Sept 2026 · Revolutionary COPD injection given to patients for first time ↗

• “This is a genuinely exciting recommendation. For the first time, we have a treatment that can give people diagnosed at an early stage precious extra time before they need to manage the full demands of the condition.”

  director of medicines evaluation at NICE · Diabetes · 30 Sept 2026 · Teplizumab drug to delay type 1 diabetes to be rolled out on the NHS ↗

• “This recommendation is the result of rigorous, evidence-based decision making, striking a balance between the benefits to patients and the best use of limited NHS funding.”

  director of medicines evaluation at Nice · Diabetes · 30 Sept 2026 · Weekly type 2 diabetes jab could replace daily injections ↗

• “I'm pleased that a commercial solution, alongside recent changes to NICE's cost-effectiveness thresholds and the use of new methods for assessing quality-of-life, has meant this treatment can now be provided on the NHS”

  director of medicines evaluation at NICE · Cancer · 30 Sept 2026 · Enhertu approved for use in England for HER2 low metastatic breast cancer ↗

• “It marked 'a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer'.”

  Director of medicines evaluation at NICE · Women's health & gynaecology · 30 Sept 2026 · New endometriosis pill approved on NHS in England ↗

• “the combined pill "marks a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer"”

  director of medicines evaluation at NICE · Women's health & gynaecology · 30 Sept 2026 · NICE recommends first combination pill for long-term treatment of endometriosis ↗

• “We're pleased to recommend linzagolix as a new treatment option for endometriosis. As a once-daily tablet taken at home, it offers a convenient way for people with endometriosis to manage their condition and helps to ease pressure on NHS services.”

  Director of Medicines at NICE · Women's health & gynaecology · 30 Sept 2026 · New at-home endometriosis treatment ↗

• “We're pleased to recommend linzagolix as a new treatment option for endometriosis. As a once-daily tablet taken at home, it offers a convenient way for people with endometriosis to manage their condition and helps to ease pressure on NHS services.”

  director of medicines evaluation at NICE · Women's health & gynaecology · 30 Sept 2026 · Linzagolix approved as second at-home treatment option for endometriosis ↗

• “For those who are unable to take HRT for varying reasons, options have historically been limited, and we have heard clearly from patients how difficult that can be. The evidence shows fezolinetant can meaningfully reduce symptoms, and was found to be cost effective, offering value for the taxpayer. This decision will give much-needed relief to those for whom HRT is unsuitable.”

  director of medicines evaluation at NICE (the National Institute for Health and Care Excellence) · Women's health & gynaecology · 30 Sept 2026 · Alternative to HRT for menopausal hot flushes now on NHS ↗

• “This new treatment marks a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer.”

  director of medicines evaluation at Nice · Women's health & gynaecology · 29 Sept 2026 · ‘First-of-a-kind’ daily pill for endometriosis treatment approved for NHS in England ↗

• “pleased to recommend linzagolix and that it offered "a convenient way for people with endometriosis to manage their condition and helps to ease pressure on NHS services"”

  director of medicines evaluation at Nice · Women's health & gynaecology · 29 Sept 2026 · Daily endometriosis pill approved for NHS could help 1,000 women a year ↗

• “Our role is important in ensuring NHS spending on new medicines reflects the benefits they deliver while protecting valuable health resources for other essential patient services”

  director of medicines evaluation at NICE · Cancer · 29 Sept 2026 · New hope for breast cancer patients as life-extending drug now on NHS in England ↗

• “For the first time, we have a treatment that can give people diagnosed at an early stage of type 1 diabetes precious extra time before they need to manage the full demands of the condition.”

  director of medicines evaluation at NICE · Children's health · 10 Sept 2026 · Immunotherapy to delay type 1 diabetes onset approved by NICE ↗

• “This recommendation is a significant milestone for people with COPD. It offers patients and effective, targeted therapy that has shown impressive results. For people whose COPD remains uncontrolled despite existing treatments, dupilumab could offers genuine hope for a better quality of life.”

  NICE director of medicines evaluation · Respiratory (asthma/COPD) · 10 Sept 2026 · NICE approves injectable COPD treatment that can reduce flare-ups by 30% ↗

• “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing. For those who are unable to take HRT for varying reasons, options have historically been limited, and we have heard clearly from patients how difficult that can be.”

  director of medicines evaluation at NICE · Maternity & neonatal · 10 Sept 2026 · NICE backs new non-hormonal drug fezolinetant for menopausal hot flushes ↗

• “Heart failure can have a profound effect on people's daily lives, often leading to repeated hospital admissions and a reduced quality of life. Not only does finerenone have the potential to help them live well for longer, but it could also save the NHS money and free up space by reducing their risk of having to go to hospital for unplanned emergency treatment.”

  director of medicines evaluation at NICE · Heart disease & stroke · 10 Sept 2026 · NICE recommends finerenone for chronic heart failure in final draft guidance ↗

• “We're pleased to be able to recommend a treatment that has the potential to alter the course of HCM and offers new hope to people with this serious condition.”

  Director of medicines evaluation at NICE · Heart disease & stroke · 10 Sept 2026 · New pill for heart condition receives simultaneous NICE and MHRA approval ↗

• “For us to be able to approve a medicine for use in the NHS it must not only represent a step forward in treatment, but it must also represent a good use of NHS resources and taxpayers' money. These treatments do not do that.”

  director of medicines evaluation at NICE · Dementia · 8 Sept 2026 · NICE rejects drugs that can slow down Alzheimer’s ↗

• “I'm pleased we can recommend this new combination treatment, which provides another much-needed option for people with metastatic hormone-sensitive prostate cancer.”

  director of medicines evaluation at Nice · Hospital discharge / bed-blocking · 27 Aug 2026 · Prostate cancer drug that can halve death risk to be offered to thousands in England ↗

• “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing. For those who are unable to take HRT for varying reasons, options have historically been limited, and we have heard clearly from patients how difficult that can be. The evidence shows fezolinetant can meaningfully reduce symptoms, and was found to be cost-effective, offering value for the taxpayer. This decision will give much-needed relief to those for whom HRT is unsuitable.”

  director of medicines evaluation at Nice · Hospital discharge / bed-blocking · 27 Aug 2026 · Drug that prevents hot flushes to be available on NHS in England ↗

• “We know that people who have already had a heart attack or stroke are living with real fear that it could happen again. Today's decision gives thousands of people in that situation an extra layer of protection, on top of the medicines they are already taking.”

  director of medicines evaluation at Nice · Hospital discharge / bed-blocking · 27 Aug 2026 · NHS England to offer weight-loss drugs to 1.2m people to reduce risk of heart attacks and strokes ↗

• “These treatments can help people live longer, maintain their independence, communication and participation in everyday life and reduce the need for hospital care”

  Nice's director of medicines evaluation · Hospital discharge / bed-blocking · 27 Aug 2026 · NHS drugs go-ahead offers lifeline to children with rare muscle-wasting disease ↗

• “We heard clearly from patients and clinicians about the very limited options available at this stage of the disease and the substantial burden that chemotherapy places on women's lives. We are pleased that, following a robust process and a new commercial arrangement with AbbVie, we are now able to recommend this treatment for NHS use.”

  director of medicines evaluation at Nice · Hospital discharge / bed-blocking · 27 Aug 2026 · Life-prolonging drug for advanced ovarian cancer gets go-ahead in England ↗

• “This is a genuinely exciting recommendation. For the first time, we have a treatment that can give people diagnosed at an early stage of type 1 diabetes precious extra time before they need to manage the full demands of the condition.”

  director of medicines evaluation at Nice · Hospital discharge / bed-blocking · 27 Aug 2026 · Drug that delays onset of type 1 diabetes approved in England and Wales ↗

• “the framework "potentially complements NICE's approach that enables NHS patients to receive innovative and promising medicines while additional evidence is gathered on how well they work in practice"”

  director of medicines evaluation at NICE · Rare diseases · 27 Aug 2026 · A faster route to rare disease treatments: the MHRA’s proposals ↗

• “This recommendation is the result of rigorous, evidence-based decision making, striking a balance between the benefits to patients and the best use of limited NHS funding.”

  director of medicines evaluation at Nice · Diabetes · 27 Aug 2026 · Weekly type 2 diabetes jab could replace daily injections ↗

• “Moving from daily injections to a single weekly dose could make a real difference to the day-to-day lives of people with type 2 diabetes, especially those who rely on a carer, family member or healthcare professional to help them inject.”

  Director of medicines evaluation at NICE · Diabetes · 27 Aug 2026 · NICE recommends weekly insulin jab for type 2 diabetes in final draft guidance ↗

• “Moving from daily injections to a single weekly dose could make a real difference to the day-to-day lives of people with type 2 diabetes, especially those who rely on a carer, family member or healthcare professional to help them inject.”

  director of medicines evaluation at NICE · Diabetes · 27 Aug 2026 · NICE approves weekly insulin injection for patients with type 2 diabetes ↗

• “This recommendation is the result of rigorous, evidence-based decision making, striking a balance between the benefits to patients and the best use of limited NHS funding.”

  director of medicines evaluation at NICE · Diabetes · 27 Aug 2026 · Lilly’s long-acting insulin wins NICE blessing ahead of potential UK approval ↗

• “Moving from daily injections to a single, weekly dose could make a real difference to the day-to-day lives of people with T2DM, especially those who rely on a carer, family member or healthcare professional to help them inject.”

  director of medicines evaluation at NICE · Diabetes · 27 Aug 2026 · Once-weekly insulin would be ‘significant change’ for diabetes prescribers ↗

Where Helen Knight has been quoted

1. MHRA consults on new regulatory framework to make UK a global leader in rare disease therapy developmentgov.uk · 30 Sept 2026
2. Landmark new plans bring treatments for rare diseases a step closergov.uk · 30 Sept 2026
3. NICE recommends new breakthrough treatment for COPDnationalhealthexecutive.com · 30 Sept 2026
4. NICE approves new COPD treatment that cuts flare-ups by 30%openaccessgovernment.org · 30 Sept 2026
5. NHS will reconsider approving Alzheimer’s ‘wonder drugs’telegraph.co.uk · 30 Sept 2026
6. Revolutionary COPD injection given to patients for first timekcl.ac.uk · 30 Sept 2026
7. Teplizumab drug to delay type 1 diabetes to be rolled out on the NHSbbc.co.uk · 30 Sept 2026
8. Weekly type 2 diabetes jab could replace daily injectionsbbc.com · 30 Sept 2026
9. Enhertu approved for use in England for HER2 low metastatic breast canceroncology-central.com · 30 Sept 2026
10. New endometriosis pill approved on NHS in Englandbbc.com · 30 Sept 2026
11. NICE recommends first combination pill for long-term treatment of endometriosispharmaceutical-journal.com · 30 Sept 2026
12. New at-home endometriosis treatmentnationalhealthexecutive.com · 30 Sept 2026
13. Linzagolix approved as second at-home treatment option for endometriosispulsetoday.co.uk · 30 Sept 2026
14. Alternative to HRT for menopausal hot flushes now on NHSbbc.com · 30 Sept 2026
15. ‘First-of-a-kind’ daily pill for endometriosis treatment approved for NHS in Englandtheguardian.com · 29 Sept 2026
16. Daily endometriosis pill approved for NHS could help 1,000 women a yeartheguardian.com · 29 Sept 2026
17. New hope for breast cancer patients as life-extending drug now on NHS in Englandbbc.co.uk · 29 Sept 2026
18. Immunotherapy to delay type 1 diabetes onset approved by NICEpulsetoday.co.uk · 10 Sept 2026
19. NICE approves injectable COPD treatment that can reduce flare-ups by 30%pulsetoday.co.uk · 10 Sept 2026
20. NICE backs new non-hormonal drug fezolinetant for menopausal hot flushespulsetoday.co.uk · 10 Sept 2026
21. NICE recommends finerenone for chronic heart failure in final draft guidancepulsetoday.co.uk · 10 Sept 2026
22. New pill for heart condition receives simultaneous NICE and MHRA approvalpulsetoday.co.uk · 10 Sept 2026
23. NICE rejects drugs that can slow down Alzheimer’scarehomeprofessional.com · 8 Sept 2026
24. Prostate cancer drug that can halve death risk to be offered to thousands in Englandtheguardian.com · 27 Aug 2026
25. Drug that prevents hot flushes to be available on NHS in Englandtheguardian.com · 27 Aug 2026
26. NHS England to offer weight-loss drugs to 1.2m people to reduce risk of heart attacks and strokestheguardian.com · 27 Aug 2026
27. NHS drugs go-ahead offers lifeline to children with rare muscle-wasting diseasetheguardian.com · 27 Aug 2026
28. Life-prolonging drug for advanced ovarian cancer gets go-ahead in Englandtheguardian.com · 27 Aug 2026
29. Drug that delays onset of type 1 diabetes approved in England and Walestheguardian.com · 27 Aug 2026
30. A faster route to rare disease treatments: the MHRA’s proposalspharmaceutical-journal.com · 27 Aug 2026
31. Weekly type 2 diabetes jab could replace daily injectionsbbc.co.uk · 27 Aug 2026
32. NICE recommends weekly insulin jab for type 2 diabetes in final draft guidancenursinginpractice.com · 27 Aug 2026
33. NICE approves weekly insulin injection for patients with type 2 diabetespulsetoday.co.uk · 27 Aug 2026
34. Lilly’s long-acting insulin wins NICE blessing ahead of potential UK approvalfiercepharma.com · 27 Aug 2026
35. Once-weekly insulin would be ‘significant change’ for diabetes prescriberspharmaceutical-journal.com · 27 Aug 2026

Related media coverage

Recent UK press coverage of their topics — not necessarily citing them directly.

• Early-onset Alzheimer's disease shows different warning signs from established risk factorsMedical Xpress
• Earlier Alzheimer’s Treatment Could Increase Lifetime BenefitsEMJ
• Alzheimer’s disease target and drug discovery by leveraging multiomics and electronic health dataNature

Contact & links

• Staff pagehttps://www.nice.org.uk/about-us/executive-team
• Press office emailpressoffice@nice.org.ukpublished here ↗
• LinkedInhttps://uk.linkedin.com/in/helen-knight-238758179

Organisational contact points only, each taken from a page the organisation publishes itself. No personal or direct contact details are held or shown.